Recombinant Canine IL-4 Protein, CF

Formulations:
Catalog # Availability Size / Price Qty
754-CL-025/CF
Product Details
Citations (15)
FAQs
Reviews

Recombinant Canine IL-4 Protein, CF Summary

Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The ED50 for this effect is 3‑18 ng/mL.
Source
E. coli-derived canine IL-4 protein
His25-His132, with an N-terminal Met
Accession #
N-terminal Sequence
Analysis
Met
Predicted Molecular Mass
12.9 kDa

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

754-CL/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

754-CL

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: IL-4

Interleukin-4 (IL-4), also known as B cell-stimulatory factor-1, is a monomeric, approximately 13 kDa ‑ 18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1 - 3). It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four alpha -helix structure (5). Canine IL-4 is synthesized with a 24 amino acid (aa) signal sequence. Mature canine IL-4 shares 81%, 61%, 46%, 38%, and 37% aa sequence identity with feline, bovine, human, mouse, and rat IL-4, respectively. IL-4 exerts its effects through two receptor complexes (6, 7). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 R alpha and the common gamma chain (a shared subunit of the receptors for IL-2, -7, -9, -15, and ‑21). The type II receptor on nonhematopoietic cells consists of IL-4 R alpha and IL-13 R alpha 1. The type II receptor also transduces IL-13 mediated signals. IL-4 is primarily expressed by Th2-biased CD4+ T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgE in B cells, acquisition of the Th2 phenotype by naïve CD4+ T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (8-11). IL-4 plays a dominant role in the development of allergic inflammation and asthma (10, 12).

References
  1. Benczik, M. and S.L. Gaffen (2004) Immunol. Invest. 33:109.
  2. Chomarat, P. and J. Banchereau (1998) Int. Rev. Immunol. 17:1.
  3. Khatlani, T. et al. (1999) J. Vet. Med. Sci. 61:967.
  4. van der Kaaij, S.Y. et al. (1999) Immunogenetics 49:142.
  5. Redfield, C. et al. (1991) Biochemistry 30:11029.
  6. Mueller, T.D. et al. (2002) Biochim. Biophys. Acta 1592:237.
  7. Nelms, K. et al. (1999) Annu. Rev. Immunol. 17:701.
  8. Paludan, S.R. (1998) Scand. J. Immunol. 48:459.
  9. Corthay, A. (2006) Scand. J. Immunol. 64:93.
  10. Ryan, J.J. et al. (2007) Crit. Rev. Immunol. 27:15.
  11. Grone, A. (2002) Vet. Immunol. Immunopathol. 88:1.
  12. Rosenberg, H.F. et al. (2007) J. Allergy Clin. Immunol. 119:1303.
Long Name
Interleukin 4
Entrez Gene IDs
3565 (Human); 16189 (Mouse); 287287 (Rat); 397225 (Porcine); 280824 (Bovine); 403785 (Canine); 574281 (Primate); 100302454 (Rabbit)
Alternate Names
B cell growth factor 1; BCDF; B-cell stimulatory factor 1; BCGF1; BCGF-1; binetrakin; BSF1; BSF-1; IL4; IL-4; IL-4B_cell stimulatory factor 1; IL4E12; interleukin 4; interleukin-4; Lymphocyte stimulatory factor 1; MGC79402; pitrakinra

Citations for Recombinant Canine IL-4 Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

15 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma
    Authors: V Konduri, MM Halpert, YC Baig, R Coronado, JR Rodgers, JM Levitt, B Cerroni, S Piscoya, N Wilson, L DiBernardi, Z Omarbekov, L Seelhoff, V Ravi, L Douglass, WK Decker
    Cancer Gene Ther., 2019;0(0):.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Brucella canis induces canine CD4+ T cells multi-cytokine Th1/Th17 production via dendritic cell activation
    Authors: M Pujol, C Borie, M Montoya, A Ferreira, R Vernal
    Comp. Immunol. Microbiol. Infect. Dis., 2019;62(0):68-75.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Canine IL4-10 fusion protein provides disease modifying activity in a canine model of OA; an exploratory study
    Authors: EM van Helvoo, J Popov-Cele, N Eijkelkamp, K Coeleveld, MA Tryfonidou, CD Wijne, CE Hack, FPJG Lafeber, SC Mastbergen
    PLoS ONE, 2019;14(7):e0219587.
    Species: Canine
    Sample Types: Whole Blood
    Applications: Control
  4. Immunogenic potential of three transmissible venereal tumor cell lysates to prime canine-dendritic cells for cancer immunotherapy
    Authors: AJ Hernández-, MA Franco-Mol, EE Coronado-C, P Zapata-Ben, EM Gamboa, Y Ramos-Zaya, SE Santana-Kr, C Rodríguez-
    Res. Vet. Sci., 2018;121(0):23-30.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Morphologic, phenotypic, and transcriptomic characterization of classically and alternatively activated canine blood-derived macrophages in vitro
    Authors: F Heinrich, A Lehmbecker, BB Raddatz, K Kegler, A Tipold, VM Stein, A Kalkuhl, U Deschl, W Baumgärtne, R Ulrich, I Spitzbarth
    PLoS ONE, 2017;12(8):e0183572.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge
    PLoS ONE, 2016;11(8):e0161169.
    Species: Canine
    Sample Types: Cell Culture Supernates
    Applications: ELISA (Standard)
  7. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs
    PLoS Negl Trop Dis, 2016;10(5):e0004614.
    Species: Canine
    Sample Types: Recombinant Protein
    Applications: ELISA (Standard)
  8. One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis.
    Authors: Costa-Pereira C, Moreira M, Soares R, Marteleto B, Ribeiro V, Franca-Dias M, Cardoso L, Viana K, Giunchetti R, Martins-Filho O, Araujo M
    BMC Vet Res, 2015;11(0):92.
    Species: Canine
    Sample Types: Cell Culture Supernates
    Applications: ELISA (Standard)
  9. Canine distemper virus infection leads to an inhibitory phenotype of monocyte-derived dendritic cells in vitro with reduced expression of co-stimulatory molecules and increased interleukin-10 transcription.
    Authors: Qeska V, Barthel Y, Herder V, Stein V, Tipold A, Urhausen C, Gunzel-Apel A, Rohn K, Baumgartner W, Beineke A
    PLoS ONE, 2014;9(4):e96121.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.
    Authors: Xiong W, Candolfi M, Liu C
    PLoS ONE, 2010;5(6):e11074.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  11. Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model.
    Authors: Lange S, Altmann S, Brandt B, Adam C, Riebau F, Vogel H, Weirich V, Hilgendorf I, Storb R, Freund M, Junghanss C
    Exp. Hematol., 2009;37(1):143-50.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  12. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
    Authors: Mason NJ, Coughlin CM, Overley B, Cohen JN, Mitchell EL, Colligon TA, Clifford CA, Zurbriggen A, Sorenmo KU, Vonderheide RH
    Gene Ther., 2008;15(13):955-65.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Authors: Lemesre JL, Holzmuller P, Goncalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G
    Vaccine, 2007;25(21):4223-34.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  14. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Authors: Lemesre JL, Holzmuller P, Cavaleyra M, Goncalves RB, Hottin G, Papierok G
    Vaccine, 2005;23(22):2825-40.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  15. Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs.
    Authors: Fujiwara RT, Loukas A, Mendez S, Williamson AL, Bueno LL, Wang Y, Samuel A, Zhan B, Bottazzi ME, Hotez PJ, Bethony JM
    Vaccine, 2005;24(4):501-9.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Canine IL-4 Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Canine IL-4 Protein, CF and earn rewards!

Have you used Recombinant Canine IL-4 Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review